OS within a year after CARTx stratified by any CMV reactivation and CMV reactivation ≥150 IU/mL. Cumulative incidence of (A) OS by 1 year in patients with and without CMV reactivation at any level occurring before 6 weeks after CARTx (65.0%; 95% CI, 34.1-84.2, vs 76.8%; 95% CI, 61.0-86.9) and (B) OS by 1 year in patients with and without CMV reactivation ≥150 IU/mL occurring before 6 weeks after CARTx (57.1%; 95% CI, 9.3-87.6, vs 75.4%; 95% CI, 61.2-85.1). HR from univariate Cox regression is shown on the plots. HR, hazard ratio.